Form Approved
OMB NO: 0920-0740
EXPIRATION DATE: 05/31/2012
Medical Monitoring Project (MMP)
Medical Record Abstraction Form
2012 Surveillance Period Inpatient Form (SPIF)
VERSION 7.1.0
O PTIONAL- FOR LOCAL USE ONLY
MMP SPIF v7.1.0
MMP Participant ID:
Date of Admission: Date not documented
A bstraction Facility ID:
(ID of facility where abstraction is being conducted)
Inpatient medical record number:
Medical record number not documented
Patient name:
Patient residence:
Street:
City/County: State:
ZIP code:
Physician name:
|
DEPARTMENT OF HEALTH AND
HUMAN SERVICES Centers
for Disease Control & Prevention
M edical Monitoring Project (MMP)
Medical Record Abstraction Form
2012 Surveillance Period Inpatient Form (SPIF)
V7.1.0
I. ABSTRACTION AND IDENTIFICATION |
||||
MMP Participant ID: |
||||
Surveillance Period (SP)
SP start date:
(12 months prior to date of interview OR 1st contact attempt if no interview obtained) |
SP end date:
(date of interview OR 1st contact attempt if no interview obtained)
|
|||
Date of abstraction: |
Abstractor ID: |
|||
Date of admission:
Date not documented
|
Date of discharge:
Date not documented |
|||
Abstraction Facility ID:
(ID of facility where abstraction is being conducted)
|
|
|||
Was the documented care abstracted with this form given at another facility (i.e., outside the Abstraction Facility)?
|
||||
|
|
Yes Complete information about the “Care” Facility
|
Enter Care Facility ID or indicate that Care Facility was not documented or was outside jurisdiction
Care Facility ID
(ID of the facility where the documented care was provided) |
|
|
|
|
||
|
|
No Continue to Section II below |
Care Facility not documented or outside jurisdiction |
|
II. SURVEILLANCE PERIOD INPATIENT FORM SECTIONS – OPTIONAL |
||||
Is there documentation of any of the following during this inpatient stay? Yes Select all that are documented below. No This form is now complete except for optional section VIII (Remarks). |
||||
New or existing diagnoses of AIDS defining Opportunistic Illnesses (AIDS OI) Complete section III. |
Prescription or continuation of medications other than ART Complete section VI. |
|||
New or existing diagnoses of conditions other than AIDS OI Complete section IV. |
Laboratory test results, closest to admission Complete section VII. |
|||
Prescription or continuation of antiretroviral therapy (ART) closest to admission Complete section V. |
Laboratory test results, closest to discharge Complete section VII. |
|||
Prescription or continuation of antiretroviral therapy (ART) closest to discharge Complete section V. |
Laboratory test results, hepatitis screening tests Complete section VII. |
III. AIDS DEFINING OPPORTUNISTIC ILLNESSES (AIDS OI) |
||||
Is there documentation any new or existing diagnoses of AIDS defining opportunistic illnesses (AIDS OI) during this inpatient stay? Yes Select all that are documented below. No |
||||
1 Candidiasis, bronchi, trachea, or lungs |
14 Lymphoma, Burkitt’s (or equivalent term) |
|||
2 Candidiasis, esophageal |
15 Lymphoma, immunoblastic (IBL, or equivalent term) |
|||
3 Carcinoma, invasive cervical |
16 Lymphoma, primary in brain |
|||
4 Coccidioidomycosis, disseminated or extrapulmonary |
17 Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary |
|||
5 Cryptococcosis, extrapulmonary |
18 M. tuberculosis, pulmonary |
|||
6 Cryptosporidiosis, chronic intestinal (>1 month duration) |
19 M. tuberculosis, disseminated or extrapulmonary |
|||
7 Cytomegalovirus disease (other than in liver, spleen, or nodes) |
20 Mycobacterium, of other species or unidentified species, disseminated or extrapulmonary |
|||
8 Cytomegalovirus retinitis (with loss of vision) |
21 Pneumocystis jiroveci pneumonia (PCP) |
|||
9 Herpes simplex: chronic ulcer (>1 month duration) or bronchitis, pneumonitis, or esophagitis |
22 Pneumonia, recurrent in 12 month period |
|||
10 HIV encephalopathy |
23 Progressive multifocal leukoencephalopathy (PML) |
|||
11 Histoplasmosis, disseminated or extrapulmonary |
24 Salmonella septicemia, recurrent |
|||
12 Isosporiasis, chronic intestinal (>1 month duration) |
25 Toxoplasmosis of brain |
|||
13 Kaposi’s sarcoma |
26 Wasting syndrome due to HIV |
|||
IV. CONDITIONS OTHER THAN AIDS OI |
||||
Is there documentation of any new or existing diagnoses of conditions other than AIDS OI during this inpatient stay? Yes Select all that are documented below. No |
||||
1 Abscess |
19 Erythema multiforme |
37 Hypogonadism (gonadal deficiency) |
55 Prostatitis |
|
2 Alcoholism |
20 Erythroderma |
38 Hypothyroidism |
56 Psoriasis |
|
3 Anxiety disorder |
21 Fatty liver |
39 Ischemic heart disease |
57 Psychosis, including schizophrenia |
|
4 Arthritis (osteoarthritis) |
22 Fever, unexplained, >100F for 2+ weeks* |
40 Lactic acidosis |
58 Pulmonary hypertension |
|
5 Asthma |
23 Gastroesophageal reflux disease (GERD) |
41 Lipoatrophy |
59 Rash, drug-related |
|
6 Avascular necrosis |
24 Guillain-Barré syndrome |
42 Lipodystrophy |
60 Renal failure |
|
7 Buffalo hump |
25 Hearing loss, acquired |
43 Malignancy |
61 Respiratory infection, upper |
|
8 Bronchitis |
26 Hepatic (liver) failure |
44 Metabolic syndrome |
62 Respiratory infection, NOS |
|
9 Cardiomyopathy, due to HIV or unknown cause |
27 Hepatitis, alcohol-induced |
45 Myelopathy (spinal cord disease/disorder) |
63 Seborrheic dermatitis |
|
10 Cellulitis (skin infection, bacterial) |
28 Hepatitis, drug-induced |
46 Myopathy (muscular weakness or changes) |
64 Stevens-Johnson Syndrome |
|
11 Depression, diagnosed by physician |
29 Hepatitis, infectious, not drug-induced |
47 Nephrolithiasis (kidney stone) |
65 Stroke, ischemic, non- hemorrhagic |
|
12 Diabetes mellitus (DM), type 1 |
30 Hepatitis, NOS |
48 Nephropathy (kidney damage) |
66 Suicide attempt |
|
13 Diabetes mellitus (DM), type 2 |
31 Hodgkin’s lymphoma (Hodgkin’s disease) |
49 Neuropathy, cranial |
67 Thrombocytopenia, idiopathic (ITP) |
|
14 Diabetes mellitus (DM), NOS
|
32 Human papillomavirus (HPV) infection |
50 Neuropathy, peripheral |
68 Vision loss, moderate or severe; blindness |
|
15 Diarrhea, allergic/colitis |
33 Hypercholesterolemia |
51 Neuropathy, NOS |
69 Warts, anal or genital |
|
16 Diarrhea, infectious |
34 Hyperglycemia |
52 Oral candidiasis (thrush) |
70 Warts, non-anal, non- genital |
|
17 Diarrhea, NOS |
35 Hypertension (high blood pressure) |
53 Osteopenia or osteoporosis |
*in absence of a known cause |
|
18 Erectile dysfunction |
36 Hypertriglyceridemia |
54 Pneumonia |
|
IV. CONDITIONS OTHER THAN AIDS OI cont’d |
|||||
71 Other, specify:
|
|||||
72 Other, specify:
|
|||||
73 Other, specify:
|
|||||
74 Other, specify: |
|||||
75 Other, specify:
|
|||||
76 Other, specify: |
|||||
77 Other, specify: |
|||||
V. ANTIRETROVIRAL THERAPY (ART) |
|||||
Is there documentation of prescription of antiretroviral therapy (ART) during this inpatient stay? Yes Select all that are documented below. No |
|||||
Prescription or continuation closest to: |
|
||||
Admission |
Discharge |
Name |
Abbreviation |
Also Known As |
Group |
1 |
1 |
Abacavir |
ABC |
Ziagen |
NRTI |
2 |
2 |
Amprenavir |
APV |
Agenerase |
PI |
3 |
3 |
Atazanavir |
ATV |
Reyataz |
PI |
4 |
4 |
Atripla |
EFV/FTC/TDF |
|
Multi-class |
5 |
5 |
Combivir |
AZT/3TC |
|
CNRTI |
6 |
6 |
Darunavir |
DRV, TMC 114 |
Prezista |
PI |
7 |
7 |
Delavirdine |
DLV |
Rescriptor |
NNRTI |
8 |
8 |
Didanosine |
Ddl |
Videx |
NRTI |
9 |
9 |
Efavirenz |
EFV |
Sustiva |
NNRTI |
10 |
10 |
Emtricitabine |
FTC |
Emtriva |
NRTI |
11 |
11 |
Enfuvirtide |
ENF, T-20 |
Fuzeon |
FI |
12 |
12 |
Epzicom |
ABC/3TC |
|
CNRTI |
13 |
13 |
Etravirine (formerly TMC125) |
ETR |
Intelence |
NNRTI |
14 |
14 |
Fosamprenavir |
FPV |
Lexiva |
PI |
15 |
15 |
Indinavir |
IDV |
Crixivan |
PI |
16 |
16 |
Lamivudine |
3TC |
Epivir |
NRTI |
17 |
17 |
Lopinavir/Ritonavir |
LPV/RTV |
Kaletra, Meltrex |
CNRTI |
18 |
18 |
Maraviroc |
MRC |
Selzentry |
Entry inhibitor |
19 |
19 |
Nelfinavir |
NFV |
Viracept |
PI |
20 |
20 |
Nevirapine |
NVP |
Viramune |
NNRTI |
21 |
21 |
Raltegravir (formerly MK-0518) |
RAL |
Isentress |
Integrase inhibitor |
22 |
22 |
Ritonavir |
RTV |
Norvir |
PI |
23 |
23 |
Saquinavir |
SQV-HGC |
Invirase, Fortovase |
PI |
24 |
24 |
Stavudine |
d4T |
Zerit |
NRTI |
25 |
25 |
Tenofovir |
TDF |
Viread |
NRTI |
26 |
26 |
Tipranavir |
TPV |
Aptivus |
PI |
27 |
27 |
Trizivir |
ABC/3TC/AZT |
|
CNRTI |
28 |
28 |
Truvada |
FTC/TDF |
|
CNRTI |
V. ANTIRETROVIRAL THERAPY (ART) cont’d |
||||||||
Prescription or continuation closest to: |
|
|||||||
Admission |
Discharge |
Name |
Abbreviation |
Also Known As |
Group |
|||
29 |
29 |
Zalcitabine |
ddC |
Hivid |
NRTI |
|||
30 |
30 |
Zidovudine |
AZT |
Retrovir |
NRTI |
|||
31 |
31 |
Other, Specify: |
||||||
32 |
32 |
Other, Specify: |
||||||
33 |
33 |
Other, Specify: |
||||||
VI. OTHER MEDICATIONS |
||||||||
Is there documentation of prescription or continuation of medications other than ART during this inpatient stay? Yes Select all that are documented below. No |
||||||||
1 |
acarbose |
35 |
dapsone (DDS) |
|||||
2 |
acetominophen/hydrocodone |
36 |
darifenacin |
|||||
3 |
acetominophen/oxycodone |
37 |
dexamethasone |
|||||
4 |
acyclovir |
38 |
diphenhydramine |
|||||
5 |
adefovir |
39 |
doxorubicin |
|||||
6 |
albuterol |
40 |
doxorubicin lipsomal |
|||||
7 |
albuterol/ipratropium |
41 |
doxycycline |
|||||
8 |
aldesleukin |
42 |
dronabinol |
|||||
9 |
alprazolam |
43 |
enalapril |
|||||
10 |
amikacin |
44 |
enalapril/hydrochlorothiazide (HCTZ) |
|||||
11 |
amitriptyline |
45 |
entecavir |
|||||
12 |
amitriptyline/chlordiazepoxide |
46 |
epoetin alfa (EPO) |
|||||
13 |
amoxicillin |
47 |
escitalopram |
|||||
14 |
amoxicillin/clavulanate |
48 |
esomeprazole |
|||||
15 |
aspirin (ASA) |
49 |
ethambutol |
|||||
16 |
atenolol |
50 |
ethionamide |
|||||
17 |
atorvastatin |
51 |
famotidine |
|||||
18 |
azithromycin |
52 |
fexofenadine |
|||||
19 |
baclofen |
53 |
filgrastim |
|||||
20 |
bupropion |
54 |
folinic acid |
|||||
21 |
buspirone |
55 |
fluconazole |
|||||
22 |
butalbital/aspirin |
56 |
fludrocortisone |
|||||
23 |
butalbital/aspirin/caffeine (BAC) |
57 |
fluoxetine |
|||||
24 |
calcitrol |
58 |
fluphenazine |
|||||
25 |
capreomycin |
59 |
fluticasone |
|||||
26 |
cetirizine |
60 |
fluticasone/salmeterol |
|||||
27 |
chlorpropamide |
61 |
fluvastatin |
|||||
28 |
cimetidine |
62 |
foscarnet |
|||||
29 |
ciprofloxacin |
63 |
gabapentin |
|||||
30 |
citalopram |
64 |
gatifloxacin |
|||||
31 |
clonazepam |
65 |
gemfibrozil |
|||||
32 |
cromolyn |
66 |
hydrochlorothiazide (HCTZ) |
|||||
33 |
cycloserine |
67 |
hydrochlorothiazide (HCTZ)/methyldopa |
|||||
34 |
cyclosporine |
68 |
hydrochlorothiazide (HCTZ)/metoprolol |
VI. OTHER MEDICATIONS cont’d |
|||
69 |
hydrochlorothiazide (HCTZ)/triamterene |
108 |
penicillin |
70 |
imiquimod |
109 |
phenytoin |
71 |
insulin (inhaled or injectable) |
110 |
pioglitazone |
72 |
interferon alphacon-1 |
111 |
podofilox topical |
73 |
interferon alfa 2a |
112 |
podophyllin topical |
74 |
interferon alfa 2b |
113 |
pravastatin |
75 |
iodoquinol |
114 |
prednisone |
76 |
isoniazid (INH) |
115 |
propranolol |
77 |
isoniazid (INH)/pyrazinamide (PZA)/rifampin |
116 |
propranolol/hydrochlorothiazide (HCTZ) |
78 |
isoniazid (INH)/rifampin |
117 |
pyrazinamide (PZA) |
79 |
kanamycin |
118 |
ranitidine |
80 |
lansoprazole |
119 |
ribavirin |
81 |
lansoprazole/amoxicillin/clarithromycin |
120 |
rifabutin |
82 |
levofloxacin |
121 |
rifampin |
83 |
levothyroxine |
122 |
rifapentine |
84 |
lisinopril |
123 |
rosiglitazone |
85 |
lithium |
124 |
rosiglitazone/glemepiride |
86 |
loxapine |
125 |
rosuvastatin |
87 |
megestrol |
126 |
sertraline |
88 |
metformin |
127 |
sildenafil |
89 |
methadone |
128 |
somatropin |
90 |
metoclopramide |
129 |
streptomycin |
91 |
metoprolol |
130 |
tadalafil |
92 |
mirtazapine |
131 |
tamsulosin |
93 |
moxifloxacin |
132 |
telbivudine |
94 |
nalbuphine |
133 |
testosterone |
95 |
niacin |
134 |
tinidazole |
96 |
nifedipine |
135 |
trazadone |
97 |
nizatidine |
136 |
triamcinolone nasal |
98 |
octreotide |
137 |
trichloracetic acid (TCA) topical |
99 |
olanzapine |
138 |
trimethoprim/sulfamethoxazole (TMP/SMZ) |
100 |
omeprazole |
139 |
valacyclovir |
101 |
oxycodone |
140 |
valproic acid |
102 |
p-aminosalicylate |
141 |
vancomycin |
103 |
palonosetron |
142 |
vardenafil |
104 |
pantoprazole |
143 |
venlafaxine |
105 |
paroxetine |
144 |
warfarin |
106 |
peginterferon alfa 2a |
145 |
zanamivir |
107 |
peginterferon alfa 2b |
146 |
zolpidem |
147 Other, Specify: |
|||
148 Other, Specify: |
|||
149 Other, Specify: |
|||
150 Other, Specify: |
|||
151 Other, Specify: |
VII. INPATIENT LABORATORY TEST RESULTS |
||||||||||||
Is there documentation of any of the following laboratory test results during this inpatient stay? Yes Enter all that are documented for each test below. No |
||||||||||||
Laboratory tests performed closest to admission: (select all that are documented)
|
||||||||||||
|
Result |
|
||||||||||
Undetectable |
Value |
Units (select one, where applicable) |
||||||||||
1 CD4 cell count |
|
|
Cells/ mm3 or µL
Other, specify: ___________________________ |
Units not documented |
||||||||
2 CD4 cell % |
|
|
% |
|
||||||||
3 HIV viral load |
|
|
Copies/mL
Other, specify: ___________________________ |
Units not documented |
||||||||
|
Lower Limit of Detection for HIV Viral Load Test Used: Lower Limit of Detection NOT documented |
|
||||||||||
4 ALT (SGPT) |
|
|
Units /L
Other, specify: ___________________________ |
Units not documented |
||||||||
5 AST (SGOT) |
|
|
Units/L
Other, specify: ___________________________
|
Units not documented |
||||||||
6 Creatinine (Creat, Cr) |
|
|
mg/dL
Other, specify: ___________________________
|
Units not documented |
||||||||
Laboratory tests performed closest to discharge: (select all that are documented)
|
||||||||||||
|
Result |
|
||||||||||
Undetectable |
Value |
Units (select one, where applicable) |
||||||||||
1 CD4 cell count |
|
|
Cells/ mm3 or µL
Other, specify: ___________________________ |
Units not documented |
||||||||
2 CD4 cell % |
|
|
% |
|
||||||||
3 HIV viral load |
|
|
Copies/mL
Other, specify: ___________________________ |
Units not documented |
||||||||
|
Lower Limit of Detection for HIV Viral Load Test Used: Lower Limit of Detection NOT documented |
|
||||||||||
4 ALT (SGPT) |
|
|
Units /L
Other, specify: ___________________________ |
Units not documented |
||||||||
5 AST (SGOT) |
|
|
Units/L
Other, specify: ___________________________
|
Units not documented |
||||||||
6 Creatinine (Creat, Cr) |
|
|
mg/dL
Other, specify: ___________________________
|
Units not documented |
||||||||
INFECTIOUS DISEASE TESTS: Hepatitis A, B, C |
||||||||||||
|
Pos(+) |
Neg(-) |
Indeterminate |
Undetectable |
Value |
Units (select one, where applicable) |
||||||
22 Anti-HAV IgG (HAV Ab IgG) |
|
|
|
|
|
|
|
|
||||
23 Anti-HAV IgM (HAV Ab IgM) |
|
|
|
|
|
|
|
|
||||
24 Anti-HAV total (HAV Ab total) |
|
|
|
|
|
|
|
|
VII. INPATIENT LABORATORY TEST RESULTS cont’d |
|||||||||||
|
Pos(+) |
Neg(-) |
Indeterminate |
Undetectable |
Value |
Units (select one, where applicable) |
|||||
25 Anti-HBc IgG (HBc Ab IgG) |
|
|
|
|
|
|
|
|
|||
26 Anti-HBc IgM (HBc Ab IgM) |
|
|
|
|
|
|
|
|
|||
27 Anti-HBc total (HBc Ab total) |
|
|
|
|
|
|
|
|
|||
28 Anti-HBe (HBe Ab)
|
|
|
|
|
|
|
|
|
|||
29 Anti-HBs IgG (HBs IgG Ab)
|
|
|
|
|
|
|
|
|
|||
30 Anti-HBs total (HBs Ab) |
|
|
|
|
|
|
|
|
|||
31 HBeAg (Hepatitis B e-antigen) |
|
|
|
|
|
|
|
|
|||
32 HBsAg (Hepatitis B surface antigen) |
|
|
|
|
|
|
|
|
|||
33 HBV DNA (PCR) |
|
|
|
|
|
IU/mL
Other, specify: _______________________ |
Units not documented |
||||
|
Lower Limit of Detection for HBV DNA (PCR) Test Used: |
|
|||||||||
Lower Limit of detection NOT documented |
|||||||||||
|
Pos(+) |
Neg(-) |
Indeterminate |
Undetectable |
Value |
Units (select one, where applicable) |
|||||
34 Anti-HCV, EIA or RIBA |
|
|
|
|
|
|
|
|
|||
35 HCV genotype |
|
|
|
|
|
|
|
|
|||
36 HCV RNA qualitative |
|
|
|
|
|
|
|
|
|||
37 HCV RNA quantitative (PCR) |
|
|
|
|
|
IU/mL
Other, specify: _______________________ |
Units not documented |
||||
|
Lower Limit of Detection for HCV RNA (PCR) Test Used: |
|
|||||||||
Lower Limit of Detection NOT documented |
MMP SPIF v7.1.0
Abstraction
MMP Participant ID: Facility ID:
(ID of facility where abstraction is being conducted)
Date of Admission:
Mo.
Day
Year
VIII. REMARKS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
File Type | application/msword |
File Title | Medical monitoring project (MMP) |
Author | Rita Morgan |
Last Modified By | Bonds, Constance (CDC/OID/NCHHSTP) |
File Modified | 2012-02-06 |
File Created | 2011-12-16 |